Restricted accessResearch articleFirst published online 2017-04
Nebulized Recombinant Human Tissue Factor Pathway Inhibitor Attenuates Coagulation and Exerts Modest Anti-inflammatory Effects in Rat Models of Lung Injury
Critically ill patients are at a constant risk of direct (e.g., by pneumonia) or indirect lung injury (e.g., by sepsis). Excessive alveolar fibrin deposition is a prominent feature of lung injury, undermining pulmonary integrity and function.
Methods:
We examined the effect of local administration of recombinant human tissue factor pathway inhibitor (rh-TFPI), a natural anticoagulant, in two well-established models of lung injury in rats. Rats received intratracheal instillation of Pseudomonas aeruginosa, causing direct lung injury, or they received an intravenous injection of Escherichia coli lipopolysaccharide (LPS), causing indirect lung injury. Rats were randomized to local treatment with rh-TFPI or placebo through repeated nebulization.
Results:
Challenge with P. aeruginosa or LPS was associated with increased coagulation and decreased fibrinolysis in bronchoalveolar lavage fluid (BALF) and plasma. Rh-TFPI levels in BALF increased after nebulization, whereas plasma rh-TFPI levels remained low and systemic TFPI activity was not affected. Nebulization of rh-TFPI attenuated pulmonary and systemic coagulation in both models, without affecting fibrinolysis. Nebulization of rh-TFPI modestly reduced the inflammatory response and bacterial growth of P. aeruginosa in the alveolar compartment.
Conclusions:
Local treatment with rh-TFPI does not alter systemic TFPI activity; however, it attenuates both pulmonary and systemic coagulopathy. Furthermore, nebulized rh-TFPI modestly reduces the pulmonary inflammatory response and allows increased bacterial clearance in rats with direct lung injury caused by P. aeruginosa.
Get full access to this article
View all access options for this article.
References
1.
BernardGR, ArtigasA, BrighamKL, CarletJ, FalkeK, HudsonL, LamyM, LegallJR, MorrisA, and SpraggR: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994; 149:818–824.
2.
GuntherA, MosaviP, HeinemannS, RuppertC, MuthH, MarkartP, GrimmingerF, WalmrathD, Temmesfeld-WollbruckB, and SeegerW: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000; 161:454–462.
3.
RijneveldAW, WeijerS, BresserP, FlorquinS, VlasukGP, RoteWE, SpekCA, ReitsmaPH, van der ZeeJS, LeviM, and van der PollT: Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med. 2006; 34:1725–1730.
4.
WygreckaM, JablonskaE, GuentherA, PreissnerKT, and MarkartP: Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb Haemost. 2008; 99:494–501.
5.
SchultzMJ, HaitsmaJJ, ZhangH, and SlutskyAS: Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia—a review. Crit Care Med. 2006; 34:871–877.
6.
CrawleyJT, and LaneDA: The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008; 28:233–242.
7.
BastaracheJA, WangL, WangZ, AlbertineKH, MatthayMA, and WareLB: Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol. 2008; 294:L874–L881.
8.
de MoerlooseP, De BenedettiE, NicodL, VifianC, and ReberG: Procoagulant activity in bronchoalveolar fluids: No relationship with tissue factor pathway inhibitor activity. Thromb Res. 1992; 65:507–518.
9.
ChoiG, VlaarAP, SchoutenM, Van't VeerC, van der PollT, LeviM, and SchultzMJ: Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J. 2007; 30:423–428.
10.
MillerDL, Welty-WolfK, CarrawayMS, EzbanM, GhioA, SulimanH, and PiantadosiCA: Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol. 2002; 26:650–658.
11.
Welty-WolfKE, CarrawayMS, MillerDL, OrtelTL, EzbanM, GhioAJ, IdellS, and PiantadosiCA: Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med. 2001; 164:1988–1996.
12.
EnkhbaatarP, OkajimaK, MurakamiK, UchibaM, OkabeH, OkabeK, and YamaguchiY: Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med. 2000; 162:1752–1759.
13.
van den BoogaardFE, HofstraJJ, van't VeerC, LeviMM, RoelofsJJ, van der PollT, and SchultzMJ: Feasibility and safety of local treatment with recombinant human tissue factor pathway inhibitor in a rat model of Streptococcus pneumoniae pneumonia. PLoS One. 2015; 10:e0127261.
14.
DixonB, SchultzMJ, HofstraJJ, CampbellDJ, and SantamariaJD: Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care. 2010; 14:445.
15.
DixonB, SchultzMJ, SmithR, FinkJB, SantamariaJD, and CampbellDJ: Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: A randomized controlled trial. Crit Care. 2010; 14:R180.
16.
SchultzMJ, RijneveldAW, FlorquinS, EdwardsCK, DinarelloCA, and van der PollT: Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol. 2002; 282:L285–L290.
17.
ChoiG, HofstraJJ, RoelofsJJ, RijneveldAW, BresserP, van der ZeeJS, FlorquinS, van der PollT, LeviM, and SchultzMJ: Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med. 2008; 36:204–210.
18.
HofstraJJ, CornetAD, de RooyBF, VlaarAP, van der PollT, LeviM, ZaatSA, and SchultzMJ: Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats. Crit Care. 2009; 13:R145.
19.
SandsetPM, AbildgaardU, and PettersenM: A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res. 1987; 47:389–400.
20.
van den BoogaardFE, BrandsX, SchultzMJ, LeviM, RoelofsJJ, van't VeerC, and van der PollT: Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost. 2011; 9:122–132.
21.
LeviM, and van der PollT: Inflammation and coagulation. Crit Care Med. 2010; 38:S26–S34.
22.
van der PollT: Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care. 2008; 12Suppl 6:S3.
23.
CarrC, BildGS, ChangAC, PeerGT, PalmierMO, FrazierRB, GustafsonME, WunTC, CreaseyAA, and HinshawLB: Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock. 1994; 44:126–137.
24.
de JongeE, DekkersPE, CreaseyAA, HackCE, PaulsonSK, KarimA, KeseciogluJ, LeviM, van DeventerSJ, and van der PollT: Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000; 95:1124–1129.
25.
LeviM, ten CateH, BauerKA, van der PollT, EdgingtonTS, BullerHR, van DeventerSJ, HackCE, ten CateJW, and RosenbergRD: Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994; 93:114–120.
26.
MoonsAH, PetersRJ, CateH, BauerKA, VlasukGP, BullerHR, and LeviM: Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost. 2002; 88:627–631.
27.
AbrahamE, ReinhartK, OpalS, DemeyerI, DoigC, RodriguezAL, BealeR, SvobodaP, LaterrePF, SimonS, LightB, SpapenH, StoneJ, SeibertA, PeckelsenC, DeDC, PostierR, PettilaV, ArtigasA, PercellSR, ShuV, ZwingelsteinC, TobiasJ, PooleL, StolzenbachJC, and CreaseyAA: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA. 2003; 290:238–247.
28.
CornetAD, HofstraJJ, VlaarAP, van den BoogaardFE, RoelofsJJ, van der PollT, LeviM, GroeneveldAB, and SchultzMJ: Nebulized anticoagulants limit coagulopathy but not inflammation in Pseudomonas aeruginosa-induced pneumonia in rats. Shock. 2011; 36:417–423.
29.
de JongeE, DekkersPE, CreaseyAA, HackCE, PaulsonSK, KarimA, KeseciogluJ, LeviM, van DeventerSJ, and van der PollT: Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis. 2001; 183:1815–1818.
30.
PapareddyP, KalleM, SorensenOE, MalmstenM, MorgelinM, and SchmidtchenA: The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. PLoS Pathog. 2013; 9:e1003803.
Welty-WolfKE, CarrawayMS, IdellS, OrtelTL, EzbanM, and PiantadosiCA: Tissue factor in experimental acute lung injury. Semin Hematol. 2001; 38:35–38.
33.
WunderinkRG, LaterrePF, FrancoisB, PerrotinD, ArtigasA, VidalLO, LoboSM, JuanJS, HwangSC, DugernierT, LaRosaS, WitteboleX, DhainautJF, DoigC, MendelsonMH, ZwingelsteinC, SuG, and OpalS: Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med. 2011; 183:1561–1568.
34.
HoneybourneD: Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr Opin Pulm Med. 1997; 3:170–174.
35.
TuinmanPR, DixonB, LeviM, JuffermansNP, and SchultzMJ: Nebulized anticoagulants for acute lung injury—a systematic review of preclinical and clinical investigations. Crit Care. 2012; 16:R70.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
